U.S. drug shortages climb to 227 active cases in Q2 2026
The United States reported a rise in active medication shortages during the second quarter of 2026, with the total reaching 227.
The increase signals growing pressure on the pharmaceutical supply chain and could affect patient access to essential therapies.
The brief also touched on other industry developments, noting that GlaxoSmithKline disclosed a financial loss linked to a clinical trial and that Eli Lilly faced criticism from a U.K. trade group for breaching voluntary industry codes.
These issues underscore the broader challenges facing drug manufacturers and regulators as they navigate supply constraints and compliance matters.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that